Protalix BioTherapeutics’ (PLX) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Protalix BioTherapeutics (NYSE:PLX) in a research report report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2026 earnings at $0.01 EPS, FY2026 earnings at $0.26 EPS, Q1 2027 earnings at $0.01 EPS, Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.04 EPS and Q4 2027 earnings at $0.08 EPS.

Protalix BioTherapeutics Price Performance

PLX stock opened at $2.14 on Thursday. The business has a 50 day simple moving average of $2.61 and a 200-day simple moving average of $2.20. The firm has a market capitalization of $172.42 million, a PE ratio of -16.46 and a beta of -0.26. Protalix BioTherapeutics has a 1 year low of $1.32 and a 1 year high of $3.19.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. R Squared Ltd acquired a new position in shares of Protalix BioTherapeutics during the 4th quarter valued at about $26,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Protalix BioTherapeutics during the second quarter worth about $27,000. SG Americas Securities LLC acquired a new stake in Protalix BioTherapeutics during the fourth quarter worth about $31,000. Bank of America Corp DE raised its stake in Protalix BioTherapeutics by 364,766.7% during the second quarter. Bank of America Corp DE now owns 21,892 shares of the company’s stock worth $32,000 after purchasing an additional 21,886 shares during the period. Finally, Marshall Wace LLP purchased a new position in Protalix BioTherapeutics during the fourth quarter worth about $34,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics News Summary

Here are the key news stories impacting Protalix BioTherapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS outlook to $0.26 (from $0.20) — a meaningful lift to next‑year profitability expectations that supports upside versus current valuations. MarketBeat PLX Coverage
• Positive Sentiment: HC Wainwright sharply increased its Q2 2026 EPS forecast to $0.27 (from $0.05), implying a strong quarter that could drive positive sentiment if results or company commentary confirm the beat. MarketBeat PLX Coverage
• Positive Sentiment: HC Wainwright reiterated a Buy rating with a $12 price target — a large premium to the current trading level that signals substantial analyst confidence in longer‑term upside. HC Wainwright Reiterates Buy (AmericanBankingNews)
• Positive Sentiment: Zacks Research upgraded its FY2026 EPS view to $0.17 (from -$0.06), improving near‑term earnings expectations from that shop. MarketBeat PLX Coverage
• Neutral Sentiment: HC Wainwright published a slate of forward-quarter and multi‑year estimates (including FY2027 at $0.14 and a series of quarter‑level forecasts) — useful as guidance but dependent on upcoming quarterly results for validation. MarketBeat PLX Coverage
• Negative Sentiment: HC Wainwright trimmed several near‑term quarter estimates: Q1 2026 to ($0.01) (from $0.04), Q3 2026 to ($0.01) (from $0.05 previously), and Q4 2026 to $0.01 (from $0.06) — reductions that increase short‑term earnings risk and can pressure sentiment into upcoming reports. MarketBeat PLX Coverage
• Negative Sentiment: Zacks lowered its FY2027 EPS to $0.00 (from $0.08), reducing next‑year upside in that shop’s view and adding to mixed analyst signals. MarketBeat PLX Coverage

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.